Abstract
Preeclampsia is an important syndrome complicating pregnancy. While the pathogenesis of preeclampsia is not entirely known, poor placental perfusion leading to widespread maternal endothelial dysfunction is accepted as a major mechanism. It has been suggested that altered placental expression of matrix metalloproteinases (MMPs) may cause shallow cytotrophoblastic invasion and incomplete remodeling of the spiral arteries. MMPs are also thought to link placental ischemia to the cardiovascular alterations of preeclampsia. In fact, MMPs may promote vasoconstriction and surface receptors cleavage affecting the vasculature. Therefore, the overall goal of this review article is to provide an overview of the pathophisiology of preeclampsia, more specifically regarding the role of MMPs in the pathogenesis of preeclampsia and the potential of MMP inhibitors as therapeutic options.
Keywords: Hypertension, hypertensive disorders, matrix metalloproteinases, preeclampsia, pregnancy, therapy, Chronic hypertension, Gestational hypertension, CARDIOVASCULAR ADAPTATIONS, renin-angiotensin-aldosterone system (RAAS)
Current Drug Targets
Title:Matrix Metalloproteinases as Drug Targets in Preeclampsia
Volume: 14 Issue: 3
Author(s): Ana C.T. Palei, Joey P. Granger and Jose E. Tanus-Santos
Affiliation:
Keywords: Hypertension, hypertensive disorders, matrix metalloproteinases, preeclampsia, pregnancy, therapy, Chronic hypertension, Gestational hypertension, CARDIOVASCULAR ADAPTATIONS, renin-angiotensin-aldosterone system (RAAS)
Abstract: Preeclampsia is an important syndrome complicating pregnancy. While the pathogenesis of preeclampsia is not entirely known, poor placental perfusion leading to widespread maternal endothelial dysfunction is accepted as a major mechanism. It has been suggested that altered placental expression of matrix metalloproteinases (MMPs) may cause shallow cytotrophoblastic invasion and incomplete remodeling of the spiral arteries. MMPs are also thought to link placental ischemia to the cardiovascular alterations of preeclampsia. In fact, MMPs may promote vasoconstriction and surface receptors cleavage affecting the vasculature. Therefore, the overall goal of this review article is to provide an overview of the pathophisiology of preeclampsia, more specifically regarding the role of MMPs in the pathogenesis of preeclampsia and the potential of MMP inhibitors as therapeutic options.
Export Options
About this article
Cite this article as:
C.T. Palei Ana, P. Granger Joey and E. Tanus-Santos Jose, Matrix Metalloproteinases as Drug Targets in Preeclampsia, Current Drug Targets 2013; 14 (3) . https://dx.doi.org/10.2174/1389450111314030004
DOI https://dx.doi.org/10.2174/1389450111314030004 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs)
Current Molecular Pharmacology Development of Genomics-Based Gene Expression Signature Biomarkers in Oncology and Toxicology to Facilitate Drug Discovery and Translational Medicine
Current Bioinformatics Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control
Current Clinical Pharmacology The VHL Tumor Suppressor: Master Regulator of HIF
Current Pharmaceutical Design Nitric Oxide Synthase (NOS) as Therapeutic Target for Asthma and Chronic Obstructive Pulmonary Disease
Current Drug Targets Caspases as Drug Targets in Ischemic Organ Injury
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Atrial Fibrillation and Chronic Kidney Disease in Hypertension: A Common and Dangerous Triad
Current Vascular Pharmacology Blood Pressure as a Therapeutic Target in Stroke
Current Topics in Medicinal Chemistry Management of Erectile Dysfunction: An Under-Recognition of Hypertension
Current Pharmaceutical Design Assessment of Endothelial Function by Positron Emission Tomography
Current Cardiology Reviews Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Targeting Redox Signaling in the Vascular Wall: From Basic Science to Clinical Practice
Current Pharmaceutical Design Evaluation of the Effects of 1,25 Vitamin D3 on Regulatory T Cells and T Helper 17 Cells in Vitamin D-deficient Women with Unexplained Recurrent Pregnancy Loss
Current Molecular Pharmacology Melatonin: Pharmacology, Functions and Therapeutic Benefits
Current Neuropharmacology Meet Our Associate Editor
Cardiovascular & Hematological Disorders-Drug Targets Antihyperglycemic and Antidyslipidemic Activities of the <i>Aqueous Salvia hispanica</i> Extract in Diabetic Rat
Cardiovascular & Hematological Agents in Medicinal Chemistry Thiazide Therapy in Chronic Kidney Disease: Renal and Extra Renal Targets
Current Drug Metabolism Effect of Oral Alkali Supplementation on Progression of Chronic Kidney Disease
Current Hypertension Reviews Bone Mineral Density in Type 2 Diabetes Patients with Charcot Arthropathy
Current Diabetes Reviews COVID-19 in People with Diabetes: Epidemiological Perspectives and Public Health Actions in the Middle East and North Africa (MENA) Region
Current Diabetes Reviews